Canakinumab

證據等級: L5

預測適應症: 10 個

Canakinumab: From Cryopyrin-Associated Periodic Syndrome to Familial Mediterranean Fever (Autosomal Dominant)

One-Sentence Summary

Canakinumab (Ilaris) is a fully human anti-IL-1β monoclonal antibody originally approved for Cryopyrin-Associated Periodic Syndromes (CAPS), encompassing familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease. The TxGNN model predicts it may be effective for Familial Mediterranean Fever (Autosomal Dominant), supported by 7 clinical trials and 20 publications — a prediction further validated by existing FDA and EMA approval for colchicine-resistant FMF. This is the highest-evidence actionable candidate in this analysis (L1), with all other top-ranked predictions (hepatic infarction, hepatic veno-occlusive disease, peliosis hepatis, monosomy X, liver angiosarcoma) assessed as mechanistically unsupported and recommended for Hold pending further investigation.

Quick Overview

Item	Content
Original Indication	Cryopyrin-Associated Periodic Syndrome (CAPS) — FCAS, Muckle-Wells Syndrome, NOMID
Predicted New Indication	Familial Mediterranean Fever, Autosomal Dominant
TxGNN Prediction Score	99.41%
Evidence Level	L1 (≥2 completed Phase 3 RCTs)
Canada Market Status	Not marketed (0 DINs)
Number of DINs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Canakinumab is a fully human IgG1/κ monoclonal antibody that selectively neutralizes IL-1β, preventing it from binding to its receptor and blocking the downstream NF-κB–driven inflammatory cascade. The drug was first clinically validated in CAPS, where gain-of-function mutations in the NLRP3 gene cause constitutive inflammasome assembly, excess caspase-1 activation, and IL-1β hypersecretion — resulting in systemic fever, urticarial rash, sensorineural hearing loss, and amyloidosis.

Familial Mediterranean Fever (FMF) converges on the same terminal effector through a distinct genetic route. FMF is caused by mutations in the MEFV gene encoding pyrin, a natural repressor of the pyrin inflammasome. Loss-of-function or hypomorphic pyrin leads to unrestrained IL-1β release, driving recurrent self-limited attacks of high fever, peritonitis, pleuritis, and arthritis. If inadequately treated, chronic IL-1β–driven inflammation leads to secondary AA amyloidosis with end-stage renal disease — the most feared long-term complication. The autosomal dominant form (AD-FMF), arising from heterozygous MEFV variants with variable penetrance, follows the same IL-1β–centered pathogenic axis.

Because both CAPS and FMF culminate in inflammasome-driven IL-1β excess, Canakinumab’s mechanism transfers directly. This is not merely a model-predicted extrapolation — the FDA approved Canakinumab for colchicine-resistant FMF, HIDS/MKD, and TRAPS in 2016 (following the landmark CLUSTER Phase 3 programme), and EMA approval followed. The TxGNN score of 99.41% is consistent with this established mechanistic and clinical evidence base.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00465985	Phase 3	Completed	35	Pivotal three-part RCT (open-label run-in → randomized double-blind placebo-controlled withdrawal → open-label extension) in Muckle-Wells Syndrome. Demonstrated that Canakinumab significantly maintained disease remission vs. placebo; core regulatory submission study.
NCT00685373	Phase 3	Completed	166	Largest long-term open-label safety and efficacy study (≥6 months, some patients >12 months) across FCAS, MWS, and NOMID. Provided the primary long-term safety dataset supporting initial CAPS approval.
NCT01302860	Phase 3	Completed	17	One-year multicenter study in CAPS patients aged ≤4 years; assessed safety, efficacy, tolerability, and critically, the interaction with childhood immunization schedules.
NCT01576367	Phase 3	Completed	17	Open-label extension for patients completing NCT01302860; evaluated long-term safety, sustained efficacy, and normalization of acute-phase reactants (CRP, SAA) over time.
NCT00991146	Phase 3	Completed	19	Japanese-population CAPS study (FCAS, MWS, NOMID) with 24-week treatment and extension until Japanese market approval; established efficacy data for East Asian patients.
NCT01242813	Phase 2	Completed	20	Open-label 4-month treatment + 6-month follow-up in active TRAPS patients; safety and proof-of-concept for IL-1β inhibition in additional periodic fever syndromes, forming the basis for Phase 3 CLUSTER design.
NCT06838143	N/A	Recruiting	25	REASSURE: Post-marketing non-interventional real-world study evaluating safety and effectiveness of Ilaris in CAPS, colchicine-resistant FMF (crFMF), TRAPS, HIDS/MKD, and sJIA in clinical practice settings (2025–2028).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29768139	2018	Phase 3 Trial Summary	N Engl J Med	CLUSTER programme results: Canakinumab significantly reduced attack frequency vs. placebo in FMF, HIDS/MKD, and TRAPS; remission rates were substantially higher with Canakinumab across all three syndromes. Primary evidence for FDA 2016 indication expansion.
35874710	2022	Systematic Review	Front Immunol	Comprehensive systematic review of all approved IL-1 blockers (anakinra, canakinumab, rilonacept) across autoinflammatory and immune-mediated disorders; confirms canakinumab’s superior half-life advantage and consistent efficacy across CAPS, FMF, TRAPS, HIDS, and sJIA.
37769252	2024	Systematic Review + Meta-analysis	Rheumatology (Oxford)	Meta-analysis of anti-IL-1 treatment (including canakinumab) efficacy and safety in FMF; provides quantitative pooled estimates for attack reduction and acute-phase reactant normalization in colchicine-resistant or colchicine-intolerant patients.
40040547	2025	Comparative Cohort	Int J Rheumatic Dis	Head-to-head comparison of canakinumab with vs. without concomitant colchicine in FMF patients; evaluated attack characteristics, CRP/SAA levels, and renal outcomes — informing combination therapy strategy.
36062765	2022	Clinical Outcomes Review	Clin Exp Rheumatol	Detailed review of IL-1 inhibition in FMF: indications for switching from colchicine, clinical response benchmarks, dosing considerations, and long-term outcomes including amyloidosis prevention.
32806879	2020	Comprehensive Review	Turk J Med Sci	Contemporary FMF review from pathogenesis to treatment; covers pyrin inflammasome mechanisms, MEFV mutation classification, diagnostic updates, and the evolving role of anti-IL-1 biologics.
36961326	2023	Cohort Study	Rheumatology (Oxford)	First dedicated study of canakinumab withdrawal feasibility in pediatric colchicine-resistant FMF; established a structured tapering and discontinuation protocol — important for real-world treatment management.
28362189	2017	Expert Review	Expert Rev Clin Immunol	Focused expert review of canakinumab in FMF; covers pharmacology, colchicine-resistant patient profiles, clinical trial outcomes, and position in the treatment algorithm.
31365342	2019	Clinical Cohort	Eur J Rheumatol	Real-world data on canakinumab in colchicine-unresponsive FMF patients; reported clinical response rates and normalization of inflammatory markers in a Turkish cohort.
34684086	2021	Review	Medicina (Kaunas)	Amyloidosis and glomerular disease in FMF; underscores the critical importance of sustained IL-1β suppression (including with canakinumab) in preventing secondary AA amyloidosis and end-stage renal failure.

Canada Market Information

Canakinumab currently has no approved Drug Identification Numbers (DINs) in Canada and is not marketed for any indication.

Context: While Health Canada approval is absent, the US FDA approved Canakinumab (Ilaris, Novartis) in June 2009 for CAPS and expanded the label in 2016 to include colchicine-resistant FMF, HIDS/MKD, and TRAPS. EMA approval for the same spectrum of autoinflammatory diseases is also in place. Canadian patients with confirmed CAPS or colchicine-resistant FMF who require Canakinumab currently depend on Health Canada’s Special Access Program (SAP).

Safety Considerations

Full prescribing information from a Canadian product monograph is unavailable for this analysis. Based on published Phase 3 clinical trial data and the FDA prescribing information, the following safety signals are relevant:

Serious and Opportunistic Infections: IL-1β inhibition impairs host defense against bacterial infections, particularly encapsulated organisms. Active tuberculosis, untreated latent TB, serious active infections, and immunocompromised states are contraindications or require mandatory screening before initiation.
Neutropenia: Transient neutropenia has been reported; complete blood count (CBC with differential) monitoring is recommended before and periodically during treatment.
Live Vaccines: Contraindicated during canakinumab treatment. Inactivated vaccines may be given but immunological response may be reduced. The NCT01302860 trial specifically studied childhood vaccination interactions in young CAPS patients.
Hypersensitivity: Anaphylaxis and serious hypersensitivity reactions have been reported; appropriate medical support must be available at time of injection.
Lipid and Liver Parameters: Transient elevations in lipids and liver enzymes have been observed; monitoring is warranted.
Macrophage Activation Syndrome (MAS): In patients with sJIA, MAS has occurred; clinicians should be vigilant for features of MAS/HLH.

Please refer to the full product monograph / package insert for comprehensive prescribing information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Canakinumab has a fully characterized IL-1β–targeting mechanism that directly addresses the core pathogenic driver of FMF, and has been validated through multiple completed Phase 3 RCTs (CLUSTER programme, published in the New England Journal of Medicine) with subsequent FDA and EMA approval for colchicine-resistant FMF. The TxGNN score of 99.41% is consistent with this level of established evidence. The primary gap is the absence of a Canadian market authorization, not a lack of clinical proof.

To proceed, the following is needed:

Regulatory pathway clarification: Determine whether Novartis Canada has submitted or plans to submit a New Drug Submission (NDS) to Health Canada for CAPS and FMF indications; if not, evaluate a third-party or compassionate access pathway.
SAP access mapping: Confirm current Health Canada Special Access Program (SAP) utilization in Canada to understand the actual patient population already receiving canakinumab and any real-world Canadian safety signal.
Safety data gap closure (DG001): Obtain the Canadian labelling equivalent (US FDA prescribing information / EMA SmPC) to complete the formal safety assessment required for S1 evaluation.
MOA documentation (DG002): Retrieve the DrugBank MOA entry for DB06168 to formally document the IL-1β neutralization mechanism in the Evidence Pack.
Patient population definition: Specify whether the target indication is pediatric vs. adult FMF, colchicine-resistant FMF specifically, or the broader autoinflammatory syndrome spectrum — as this determines the applicable Phase 3 dataset and labelling strategy.
Health economics assessment: Given the high cost of biologic therapy and the rarity of colchicine-resistant FMF in Canada, a budget impact and cost-effectiveness analysis relative to anakinra (an alternative IL-1 blocker) would support payer engagement.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.